OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

May 2nd 2024

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

Dr Liu on the Ongoing Investigation of Zidesamtinib in ROS1+ Tumors

May 2nd 2024

Stephen V. Liu, MD, discusses the potential benefits and ongoing investigation of zidesamtinib for patients with ROS1-positive tumors.

Dr Oluwole on the Use of CAR T-Cell Therapy in Autoimmune Disorders

May 2nd 2024

Olalekan O. Oluwole, MBBS, MD, discusses the feasibility of using CAR T-cell therapy in patients with nonhematologic autoimmune disorders.

Dr Jallouk on Preventing Post-Transplant Relapse in R/R Hematologic Malignancies

May 2nd 2024

Andrew P. Jallouk, BS, MD, PhD, discusses research assessing post-transplant relapse prevention strategies in patients with hematologic malignancies.

Dr Daver on the Targeted Therapy Development Pipeline in AML

May 1st 2024

Naval G. Daver, MD, discusses the future of targeted therapy development for patients with acute myeloid leukemia.

Dr Jabbour on the Results of the PhALLCON Trial in Newly Diagnosed Ph+ ALL

May 1st 2024

Elias Jabbour, MD, discusses outcomes from the phase 3 PhALLCON trial in patients with Ph-positive acute lymphoblastic leukemia.

Dr Tripathy on the HER2+ Breast Cancer Treatment Paradigm

May 1st 2024

Debu Tripathy, MD, discusses the current state of the HER2-positive breast cancer treatment paradigm.

Dr Iyer on the Design of the COMMANDS Trial in Lower-Risk MDS With Anemia

May 1st 2024

Sunil Iyer, MD, discusses the design of the phase 3 COMMANDS trial in patients with lower-risk myelodysplastic syndrome with anemia.

Dr Eroglu on Addressing Unmet Needs in Mutant Melanoma

May 1st 2024

Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.

Dr Eroglu on Ceritinib With or Without Trametinib in Pretreated Advanced Melanoma

May 1st 2024

Zeynep Eroglu, MD, discusses the efficacy and safety of ceritinib as monotherapy and in combination with trametinib in pretreated advanced melanoma.

Dr Hartwich on Preclinical Findings for Y3 Plus Chemotherapy in Ovarian Cancer

May 1st 2024

Yang Yang Hartwich, PhD discusses a study delving into the mechanisms underlying chemoresistance in ovarian cancer.

Dr Ahluwalia on Advancements in the Management of Brain Metastases

April 30th 2024

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.

Dr Diaz on the Evolution of Precision Medicine in Cervical Cancer

April 30th 2024

John Paul Diaz, MD, discusses the evolving use of precision medicine approaches in cervical cancer management.

Dr Kopetz on the Future Utility of Adagrasib/Cetuximab in KRAS G12C–Mutant CRC

April 30th 2024

Scott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.

Dr Konecny on PROs From the MIRASOL Trial in Advanced Ovarian Cancer

April 30th 2024

Gottfried Konecny, MD, discusses the importance of evaluating PROs in patients with platinum-resistant ovarian cancer receiving mirvetuximab soravtansine.

Dr Jain on the VERONA Study in Higher-Risk MDS

April 30th 2024

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.

Dr Aldoss on the Mechanism of Action of Ponatinib in Ph+ ALL

April 29th 2024

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.

Dr Nanda on HER2-Low Status Testing in Early-Stage Breast Cancer

April 29th 2024

Rita Nanda, MD, discusses the importance of testing for HER2-low status in patients with early-stage breast cancer.

Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma

April 29th 2024

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.

Dr Fujiwara on the FDA Approval of Tisotumab Vedotin for Recurrent Cervical Cancer

April 29th 2024

Keiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.